Roche

(IN BRIEF) Roche has unveiled Elecsys® HBeAg quant, a new immunoassay designed to detect the presence and quantity of the hepatitis B e antigen (HBeAg) in human serum and plasma. This diagnostic tool simplifies the process for both clinicians and … Read the full press release →

(IN BRIEF) Roche has introduced the Elecsys®Anti-HEV IgM and Elecsys Anti-HEV IgG immunoassays for detecting hepatitis E virus (HEV) infections in regions accepting the CE mark. These tests aim to assist clinicians in diagnosing the cause of patients’ symptoms, determining … Read the full press release →

(IN BRIEF) Roche, a leading healthcare company, has announced that its Elecsys Neurofilament Light Chain (NfL) test for Multiple Sclerosis (MS) has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA). The Elecsys NfL test is designed … Read the full press release →

(IN BRIEF) Pfizer and BioNTech have announced positive topline results from a Phase 1/2 study of their mRNA-based combination vaccine program for influenza and COVID-19. The lead formulations showed robust immune responses to influenza A, influenza B, and SARS-CoV-2 strains. … Read the full press release →

(IN BRIEF) BioNTech SE is set to reveal its financial results for the third quarter of 2023 on November 6th, 2023. The company invites investors and the public to participate in a conference call and webcast at 8:00 a.m. ET … Read the full press release →

(IN BRIEF) BioNTech will be presenting updates on multiple programs across its oncology pipeline at the European Society for Molecular Oncology (ESMO) Congress 2023. These updates include data on investigational CAR-T and ex-vivo T cell therapies, a novel ADC (antibody-drug … Read the full press release →

(IN BRIEF) Roche has announced positive late-breaking data from the Phase III OCARINA II study, which demonstrates the effectiveness of OCREVUS as a twice-yearly, 10-minute subcutaneous injection for patients with relapsing or primary progressive multiple sclerosis (RMS or PPMS). The … Read the full press release →

(IN BRIEF) Roche has reported positive outcomes from the RAINBOWFISH study, an investigation into the efficacy and safety of Evrysdi® (risdiplam) in babies with pre-symptomatic spinal muscular atrophy (SMA). The study, which included 26 infants aged from birth to six … Read the full press release →